news
Gilead set to acquire Forty Seven for $4.9bn later in 2020
Gilead's acquisition of Forty Seven was unanimously approved by both companies' Boards of Directors, for $95.50 per share.
List view / Grid view
Pipelines
article
Creating a modern business landscape in biopharma
There are many business challenges to developing a biologics drug, one of which is effective data management. In this article, Unjulie Bhanot focuses on efficient data management policies and systems, and how they could improve biologics product development processes.
news
Biomanufacturing sector set to ‘boost its efficiency’
The next five years will see game-changing improvements made in upstream, downstream and continuous bioprocessing, predicts one industry specialist...
news
CPhI Annual Report reveals slow and discouraging trends in current drug pipelines
CPhI Worldwide report states the current drugs pipeline is discouraging and slowing simple manufacturing innovations...
